Objective: The metabolic syndrome (MetS) is a cluster of metabolic disorders including, elevated fasting plasma glucose, abdominal obesity, elevated blood pressure, high serum triglyceride and low high-density lipoprotein (HDL) levels. It increases risk of cardiovascular disease and premature mortality. Incretin hormones specifically Glucagon like peptide-1 (GLP-1) are secreted from gut in response to food ingestion and enhance insulin secretion. Because these hormones have multifactorial effects on food intake, blood pressure, and lipid metabolism, the relationship between MetS and incretin hormones is of utmost attention. But the results of this relationship are controversial. The aim of this study was to investigate the relationship between serum GLP-1 hormone with criteria for MetS.
Material and Methods: In this study, twenty-seven patients who underwent coronary angiography were included. Anthropometric measurements such as body mass index (BMI) and other required data were collected by questionnaires. Glucose, insulin, cholesterol, triglyceride, HDL and low-density lipoprotein (LDL) levels in serum samples were measured with using autoanalyzer. Measurement of plasma GLP-1 concentration done with ELISA method. Statistical analysis was performed using SPSS software.
Results: Insulin resistance index (HOMA-IR) was higher (p= 0.149) and HDL level was lower (P= 0.292) in patients whose BMI ≥ 30 kg/m2 compared with the patients whose BMI < 30 kg/m2. Plasma GLP-1 level was positively correlated with serum glucose concentration (r= 0.344; p= 0.079), and was negatively correlated with HDL level (r= -0.128; p= 0.525). According to the angiography data, 20 patients had coronary artery disease (CAD). Individuals with CAD had lower plasma GLP-1 level than who did not have CAD (p= 0.334).
Conclusions: These observations prove that GLP-1 play an important role in development of MetS. The results obtained will provide new insights for incretin-based treatments for MetS.
This research was partially supported by Marmara University Research Foundation (No: TYL-2021-10193)
Anahtar Kelimeler: Metabolic syndrome, Glucagon like peptide-1 (GLP-1), Lipids, Coronary artery disease
|
